No Data
No Data
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results From the Volixibat VANTAGE and VISTAS Studies on June 17, 2024
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC).
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on June 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
Mirum Pharmaceuticals(MIRM.US) Director Sells US$128.4K in Common Stock
$Mirum Pharmaceuticals(MIRM.US)$ Director Ramasastry Saira sold 5,000 shares of common stock on Jun 5, 2024 at an average price of $25.68 for a total value of $128.4K.Source: Announcement What is stat
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $58
H.C. Wainwright analyst Ed Arce maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $58.According to TipRanks data, the analyst has a success rate of 40.0%
Mirum Pharmaceuticals Presents Long-Term Data From Its LIVMARLI Studies In ALGS And PFIC Highlighted At The EASL Annual Congress, June 5-8, 2024, In Milan, Italy
- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome- Long-term extension data from LIVMARLI PFIC studies highlight improvement in
Express News | Long-Term Data From Mirum’s Livmarli Studies in Algs and Pfic Highlighted at Easl Congress
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.